Colin James Thomas, MD

Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Colin James Thomas, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Medical School: Temple University School of Medicine
  • Residency: Thomas Jefferson University Hospital
  • Fellowship: Thomas Jefferson University Hospital

Reviews

Average Rating

279 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
dr thomas is a good listener and builds trust with his patients
Anonymous
May 2026
i could not be any happier with dr. thomas
Anonymous
April 2026
dr. thomas is always very thorough and covering all the topics intended for our meeting
Anonymous
April 2026
outstanding physician

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Thomas is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Colin J Thomas, Caroline S Myers, Jina Chung, Daniel Landsburg, Sunita D Nasta, Jakub Svoboda, Elise A Chong, Stephen J Schuster, Jordan Carter, Michael Cook, Emily Tomasulo, Omar Elghawy, Michael LaRiviere, Harper Hubbeling, John P Plastaras, Alain H Rook, Jennifer Villasenor-Park, Marco Ruella, Ellen Kim, Stefan K Barta Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden , Blood Neoplasia, 3(3): 2026


Michael Schneider, Luca Paruzzo, Federico Stella, Julia Han Noll, Matthew Ho, Victor Babatunde, Bianca Ho, Pooja Devi, Elise A Chong, Stefan K Barta, Sunita D Nasta, Jakub Svoboda, Jordan Carter, Michael R Cook, Nasheed M Hossain, Colin J Thomas, Vrutti Patel, Vitor B de Souza, Mohannad H Alkhatib, Ziyu Li, Melody Tan, Peter Michener, Puneeth Guruprasad, Antonio Imparato, Alberto Carturan, Patrizia Porazzi, Joseph A Fraietta, Stephen J Schuster, Ivan Maillard, Marco Ruella, Daniel J Landsburg Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy , Nature Communications : 2026


Colin J. Thomas, Ming Jung Koh, Omar Elghawy, et al. Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium , Leukemia & Lymphoma: 2026


John Sharp, Paolo Strati, Subodh Bhatta, Jennifer J Huang, Colin J Thomas, Omar Elghawy, Daniel Reef, Alexander Micah Gorzewski, John Seng Wang, Geoffrey Shouse, Catherine Reinert, Andinet Teferra, Esteban Toro Velez, Ari Pelcovits, Thomas A Ollila, William Bennett Clark, Victor Yazbeck, Joseph E Maakaron, Manali Kamdar, Lindsey A Fitzgerald, Alexey V Danilov, Reem Karmali, Natalie S Grover, Stefan K Barta, Timothy J Voorhees, Andy I Chen, Mazyar Shadman, Sairah Ahmed, Narendranath Epperla Real-World Outcomes and Toxicities of CAR-T in Relapsed/Refractory Follicular Lymphoma: A Multicenter Cohort Study , Blood Advances: 2026


Daniel J Landsburg, Nancy Musoke, Caren Gentile, Taylor R Brooks, Sunita D Nasta, Stefan K Barta, Jordan S Carter, Elise A Chong, Jakub Svoboda, Stephen J Schuster, Colin J Thomas, Emily B Tomasulo, Michael R Cook, Jennifer J D Morrissette, Paolo F Caimi, Brian T Hill Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma , Leukemia: 2026


Adam J Olszewski, Thomas A Ollila, Dai Chihara, Geoffrey Shouse, Natalie Grover, Reem Karmali, Pallawi Torka, Colin Thomas, Praveen Ramakrishnan Geethakumari, Stefan K Barta, Nancy L Bartlett, Narendranath Epperla Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma , Haematologica: 2025


Sharma, M., Myrdal, C., Thomas, C., Chung, J., Barta, S. & Kim, E. A Rare Case of Tender Facial Nodules as a Presenting Sign of Lymphoplasmacytic Lymphoma , JAAD Case Reports, 66: 2025,6:58-61.


Colin J. Thomas & Stefan K. Barta The Promise of Immunotherapies in T-Cell Lymphoma , Clinical Lymphoma, Myeloma & Leukemia, S2152-2650(25): 2025,03399-3.


Nikita K Dave, Veronica Carvajal, Alex C Watts, Jordan S Carter, Michael Cook, Colin Thomas, Donald E Tsai, Stephen J Schuster, James N Gerson, Stefan K Barta, Jakub Svoboda, Elise A Chong, Wei-Ting Hwang, Daniel J Landsburg, Sunita D Nasta Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma , Blood Neoplasia, 2(3): 2025,100102.


Narendranath Epperla, Geoffrey Shouse, Natalie S Grover, Pallawi Torka, Kaitlin Annunzio, Marcus Watkins, Andrea Anampa-Guzmán, Beth Christian, Colin Thomas, Stefan K Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L Bartlett, Adam J Olszewski Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study , Experimental Hematology & Oncology , 14(1): 2025